Along the same line, Allen et al. found that LTβR activation during antiangiogenic and anti-PD-L1 therapy changed approximately 15% of tumor vessels into HEVs, which correlated with a 10-fold higher number of granzyme B-activated CD8+ cells in a preclinical mouse model of GBM [182]. The gene discussed is CD8A; the disease is neoplasm.